KU study uncovers new aspect of Ewing sarcoma
LAWRENCE — A team of University of Kansas researchers is helping uncover hidden aspects of Ewing sarcoma, which may lead to the discovery of new cancer treatments.
Mizuki Azuma, associate professor of molecular biosciences, sought to go beyond the well-studied aspect of fusion protein in Ewing sarcoma, which occurs in the bones or in the soft tissue around the bones, and instead turned her attention toward an additional genetic abnormality in the cancer.
Working with Haeyoung Kim, doctoral candidate in molecular biosciences; Hyewon Park, research assistant; Evan Schulz, doctoral candidate in molecular biosciences, and Yoshiaki Azuma, professor of molecular biosciences, the team found that the reduction of EWS proteins in a cell causes abnormal cell division, which results in a daughter cell that has abnormal copy numbers of DNA. Their findings were just published in the peer-reviewed journal Frontiers in Cell and Developmental Biology.
In a healthy cell, the EWS gene encodes a multifunctional protein that is involved in gene expression, cell signaling, and RNA processing and transport. This DNA is known to be mutated in Ewing sarcoma. Specifically, the EWS gene is fused to other gene, and one copy of the EWS gene is lost in the patient. The KU team made cells that mimic the DNA condition of Ewing sarcoma, and samples were analyzed at the Microscopy and Analytical Imaging Research Resource Core Laboratory. The team discovered that the EWS normally located at a part of DNA works together with Aurora B (an important protein required for cell division), but reduced EWS induces abnormal copy numbers of DNA due to the failure in the cell division.
Azuma’s findings could lead toward new cancer treatments, as the same process that causes the reduction of the EWS gene in a cell is common across many types of cancer, including other childhood sarcoma, leukemia, melanoma and breast cancer. By pinpointing the cause of abnormal cell division in EWS, it will allow researchers to test for and discover a drug that targets the EWS phenomena, and in turn apply the same drug to cancers with similar factors.
“When you find a particular phenomenon specific to a cancer, it allows you to screen cancer drugs that specifically work only in the phenomenon. In this case, it will allow us to test if cancer drugs will kill the Ewing sarcoma cells with lower levels of EWS,” Azuma said.
The Azuma lab is applying for a grant to continue their research.
“This research was sort of a baseline study, and we aim to reveal the entire pathway in future study,” Azuma said.